X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs DISHMAN PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE DISHMAN PHARMA CADILA HEALTHCARE/
DISHMAN PHARMA
 
P/E (TTM) x 24.0 25.1 95.8% View Chart
P/BV x 6.0 3.3 180.4% View Chart
Dividend Yield % 0.8 0.7 117.3%  

Financials

 CADILA HEALTHCARE   DISHMAN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
DISHMAN PHARMA
Mar-16
CADILA HEALTHCARE/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs460374 122.9%   
Low Rs305129 236.6%   
Sales per share (Unadj.) Rs92.1197.8 46.6%  
Earnings per share (Unadj.) Rs14.821.2 69.9%  
Cash flow per share (Unadj.) Rs18.534.7 53.2%  
Dividends per share (Unadj.) Rs3.202.00 160.0%  
Dividend yield (eoy) %0.80.8 105.3%  
Book value per share (Unadj.) Rs68.0179.9 37.8%  
Shares outstanding (eoy) m1,023.7480.69 1,268.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.21.3 326.4%   
Avg P/E ratio x25.811.9 217.5%  
P/CF ratio (eoy) x20.77.2 285.6%  
Price / Book Value ratio x5.61.4 402.2%  
Dividend payout %21.69.4 229.0%   
Avg Mkt Cap Rs m391,58120,306 1,928.4%   
No. of employees `00016.90.8 2,033.2%   
Total wages/salary Rs m15,0025,355 280.2%   
Avg. sales/employee Rs Th5,594.519,252.7 29.1%   
Avg. wages/employee Rs Th890.16,459.5 13.8%   
Avg. net profit/employee Rs Th899.92,064.1 43.6%   
INCOME DATA
Net Sales Rs m94,29515,961 590.8%  
Other income Rs m1,286265 484.6%   
Total revenues Rs m95,58116,226 589.1%   
Gross profit Rs m19,0364,103 463.9%  
Depreciation Rs m3,7501,091 343.8%   
Interest Rs m450944 47.6%   
Profit before tax Rs m16,1222,334 690.9%   
Minority Interest Rs m3380-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,289624 206.7%   
Profit after tax Rs m15,1681,711 886.4%  
Gross profit margin %20.225.7 78.5%  
Effective tax rate %8.026.7 29.9%   
Net profit margin %16.110.7 150.0%  
BALANCE SHEET DATA
Current assets Rs m60,22311,018 546.6%   
Current liabilities Rs m53,0589,517 557.5%   
Net working cap to sales %7.69.4 80.8%  
Current ratio x1.11.2 98.0%  
Inventory Days Days70110 63.2%  
Debtors Days Days8835 253.1%  
Net fixed assets Rs m72,98416,304 447.6%   
Share capital Rs m1,024161 634.4%   
"Free" reserves Rs m68,57612,907 531.3%   
Net worth Rs m69,60014,516 479.5%   
Long term debt Rs m24,6844,189 589.2%   
Total assets Rs m152,20729,805 510.7%  
Interest coverage x36.83.5 1,061.0%   
Debt to equity ratio x0.40.3 122.9%  
Sales to assets ratio x0.60.5 115.7%   
Return on assets %10.38.9 115.2%  
Return on equity %21.811.8 184.9%  
Return on capital %17.917.5 102.3%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m21,2804,952 429.8%   
Fx outflow Rs m10,874697 1,560.6%   
Net fx Rs m10,4064,255 244.6%   
CASH FLOW
From Operations Rs m13,4952,786 484.3%  
From Investments Rs m-29,103-1,529 1,903.5%  
From Financial Activity Rs m23,158-941 -2,460.7%  
Net Cashflow Rs m7,556316 2,388.1%  

Share Holding

Indian Promoters % 74.8 61.4 121.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 3.7 224.3%  
FIIs % 5.9 12.7 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 22.1 49.8%  
Shareholders   44,069 46,261 95.3%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jun 22, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS